RAD Approval for Phase 1 Therapeutic Trial of RAD 402
Filed with ASX · · 2 pages · English
Sydney, Australia – 18 November 2025 – Radiopharm “Company”), a clinical-stage biopharmaceutical comp radiopharmaceuticals for areas of high unmet medica granted Bellberry Human Research Ethics Committee ( In-Human (FIH) Phase 1 clinical trial of its Kallik rein Related Peptidase 3 (KLK3)-targeting radiotherapeutic, RAD 402, for the treatment of met astatic or locally advanced prostate cancer. The
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
- RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
- Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
- RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Later from Radiopharm Theranostics
- Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
- Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
- RAD101 interim Phase 2b data - 92% achieve primary endpoint
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics